CN1145618C - 作为黄体酮受体调节剂的环氨基甲酸酯衍生物 - Google Patents

作为黄体酮受体调节剂的环氨基甲酸酯衍生物 Download PDF

Info

Publication number
CN1145618C
CN1145618C CNB008071004A CN00807100A CN1145618C CN 1145618 C CN1145618 C CN 1145618C CN B008071004 A CNB008071004 A CN B008071004A CN 00807100 A CN00807100 A CN 00807100A CN 1145618 C CN1145618 C CN 1145618C
Authority
CN
China
Prior art keywords
dihydro
oxazin
dimethyl
benzo
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008071004A
Other languages
English (en)
Chinese (zh)
Other versions
CN1349517A (zh
Inventor
张普文
�ȶ��Ҹ�
E·A·捷烈弗柯
H·弗莱彻三世
A·芬森
J·E·弗罗贝尔
智林
��ظ�
T·K·琼斯
»
C·M·特格利
J·P·爱德华兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hui Shi
Original Assignee
Ligand Pharmaceuticals Inc
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/552,633 external-priority patent/US6509334B1/en
Application filed by Ligand Pharmaceuticals Inc, American Home Products Corp filed Critical Ligand Pharmaceuticals Inc
Publication of CN1349517A publication Critical patent/CN1349517A/zh
Application granted granted Critical
Publication of CN1145618C publication Critical patent/CN1145618C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/141,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/181,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNB008071004A 1999-05-04 2000-05-01 作为黄体酮受体调节剂的环氨基甲酸酯衍生物 Expired - Fee Related CN1145618C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18301299P 1999-05-04 1999-05-04
US60/183,012 1999-05-04
US09/552,633 US6509334B1 (en) 1999-05-04 2000-04-19 Cyclocarbamate derivatives as progesterone receptor modulators
US09/552,633 2000-04-19

Publications (2)

Publication Number Publication Date
CN1349517A CN1349517A (zh) 2002-05-15
CN1145618C true CN1145618C (zh) 2004-04-14

Family

ID=26878647

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008071004A Expired - Fee Related CN1145618C (zh) 1999-05-04 2000-05-01 作为黄体酮受体调节剂的环氨基甲酸酯衍生物

Country Status (19)

Country Link
EP (1) EP1173426A1 (https=)
JP (1) JP2002543193A (https=)
KR (1) KR20010114250A (https=)
CN (1) CN1145618C (https=)
AU (1) AU766428B2 (https=)
BG (1) BG106079A (https=)
BR (1) BR0010213A (https=)
CA (1) CA2371726A1 (https=)
CZ (1) CZ20013951A3 (https=)
EA (1) EA004512B1 (https=)
HU (1) HUP0201609A3 (https=)
IL (1) IL146280A0 (https=)
MX (1) MXPA01011286A (https=)
NO (1) NO321361B1 (https=)
NZ (1) NZ515355A (https=)
PL (1) PL351127A1 (https=)
SG (1) SG114650A1 (https=)
SK (1) SK15912001A3 (https=)
TR (1) TR200103286T2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0510278A (pt) * 2004-04-27 2007-10-30 Wyeth Corp método para produzir compostos, produto, e, composto
WO2006077821A1 (ja) * 2005-01-19 2006-07-27 Dainippon Sumitomo Pharma Co., Ltd. アルドステロン受容体調節剤としての芳香族スルホン化合物
US8314094B2 (en) 2007-10-05 2012-11-20 Msd K.K Benzoxazinone derivative
CN111925353B (zh) * 2020-08-31 2022-04-08 苏州大学附属第二医院 一种2-噻吩甲腈的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510235A1 (en) * 1991-04-26 1992-10-28 Dong-A Pharm. Co., Ltd. Novel benzoxazine or benzothiazine derivatives and process for the preparation of the same
AU1694295A (en) * 1994-01-28 1995-08-15 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
EP1043325B1 (en) * 1994-12-22 2004-06-16 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
DE69724630T2 (de) * 1996-10-02 2004-07-29 Bristol-Myers Squibb Pharma Co. 4,4-disubstituierte 1,4-dihydro-2h-3,1-benzoxazin-2-one die anwendbar sind als hiv-reverstranskriptase-inhibitoren, zwischenprodukte und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
TR200103286T2 (tr) 2002-07-22
EA200101176A1 (ru) 2002-04-25
HUP0201609A3 (en) 2002-12-28
AU766428B2 (en) 2003-10-16
PL351127A1 (en) 2003-03-24
BG106079A (en) 2002-05-31
KR20010114250A (ko) 2001-12-31
CN1349517A (zh) 2002-05-15
EA004512B1 (ru) 2004-04-29
JP2002543193A (ja) 2002-12-17
NZ515355A (en) 2004-02-27
SK15912001A3 (sk) 2002-06-04
NO20015378D0 (no) 2001-11-02
MXPA01011286A (es) 2003-07-14
SG114650A1 (en) 2005-09-28
CA2371726A1 (en) 2000-11-09
CZ20013951A3 (cs) 2002-05-15
HUP0201609A2 (en) 2002-08-28
EP1173426A1 (en) 2002-01-23
AU4688600A (en) 2000-11-17
BR0010213A (pt) 2002-02-19
NO20015378L (no) 2002-01-03
IL146280A0 (en) 2002-07-25
NO321361B1 (no) 2006-05-02

Similar Documents

Publication Publication Date Title
CN1141295C (zh) 作为黄体酮拮抗剂的二氢吲哚衍生物
CN1349413A (zh) 含喹唑啉酮和苯并噁嗪衍生物的避孕组合物
US7488822B2 (en) Cyclocarbamate derivatives as progesterone receptor modulators
US8329690B2 (en) Cyclothiocarbamate derivatives as progesterone receptor modulators
CN1349511A (zh) 苯并咪唑酮和类似物以及它们作为黄体酮配体的用途
CN1131856C (zh) 作为黄体酮受体调节剂的环硫代氨基甲酸酯衍生物
CN1444570A (zh) 非甾体抗炎药
CN1665510A (zh) 作为pr调节剂的环硫代氨基甲酸酯衍生物的衍生物和其用于治疗皮肤病的用途
CN1179753C (zh) 含有抗孕激素和孕激素的避孕组合物
CN1349537A (zh) 环脲和环酰胺衍生物
CN1201820C (zh) 含苯并咪唑酮和孕激素的组合物
CN1145618C (zh) 作为黄体酮受体调节剂的环氨基甲酸酯衍生物
CN1349416A (zh) 含有二氢吲哚衍生物和促孕药的避孕组合物
CN1143847C (zh) 硫代-羟吲哚衍生物
CN1145610C (zh) 作为黄体酮受体调制剂的喹唑啉酮和苯并噁嗪衍生物
CN1349538A (zh) 环氨基甲酸酯和环酰胺衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: WYETH CORP.; LEGA PHARMACY CO.,LTD.

Free format text: FORMER NAME OR ADDRESS: AMERICAN HOME PRODUCTS CORP.; LEGA PHARMACY CO.,LTD.

CP01 Change in the name or title of a patent holder

Patentee after: Wyeth Corp.

Patentee after: Ligand Pharmaceuticals, Inc.

Patentee before: American Home Products Corp.

Patentee before: Ligand Pharmaceuticals, Inc.

ASS Succession or assignment of patent right

Owner name: WYETH(AMERICAN HOME PRODUCTS)

Free format text: FORMER OWNER: WYETH(AMERICAN HOME PRODUCTS); LEGA PHARMACY CO.,LTD.

Effective date: 20061208

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20061208

Address after: new jersey

Patentee after: Hui Shi

Address before: new jersey

Co-patentee before: Ligand Pharmaceuticals, Inc.

Patentee before: Hui Shi

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee